Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COLUMN
Fairness, Not Diversity
Over the summer, I visited my brother and his family on their annual vacation to the picturesque seaside town of Torcross, England. Torcross is a beautiful little village set within the South Devon area, famous for its cracking beaches and…
To read the full story
COLUMN
- The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
- AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
- AI: Your New HR BFF (Not Your Replacement!)
December 24, 2025
- AI in HR: Navigating the Ethical Minefield
November 28, 2025
- The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…